FDA Fast-Tracks Eli Lilly Foundayo Obesity Pill Approval
The FDA has granted speedy approval to Eli Lilly’s oral GLP‑1 obesity pill Foundayo (generic orforglipron), completing its review in 50 days under a new expedited program; a pivotal NEJM trial found a mean 11.2% weight loss at 36 mg over more than 16 months (~25 lbs) versus 2.1% on placebo, with 5–10% discontinuing for gastrointestinal side effects versus nearly 3% for placebo. Foundayo is priced at $149–$349 per month (insured patients may pay about $25/month with a Lilly discount card), will be included in a federal effort to lower GLP‑1 prices, allows dosing without fasting or timing restrictions (unlike Novo Nordisk’s oral Wegovy, which has had 600,000+ prescriptions), and prompted a >4% rise in Lilly’s stock after the approval.
📌 Key Facts
- The FDA fast‑tracked approval of Eli Lilly’s oral GLP‑1 weight‑loss pill Foundayo (generic name: orforglipron), which mimics natural appetite hormones.
- The agency completed its review in 50 days under a new expedited‑approval program designed to shorten drug approval times.
- Phase‑trial results reported in NEJM showed mean weight loss of 11.2% (about 25 pounds) at the 36 mg dose over more than 16 months versus 2.1% (under 5 pounds) for placebo; 5–10% of patients on orforglipron discontinued due to gastrointestinal side effects versus nearly 3% on placebo.
- Orforglipron can be taken without fasting or timing restrictions, unlike Novo Nordisk’s competing oral Wegovy pill, which must be taken on an empty stomach with a 30‑minute wait before eating or drinking.
- U.S. pricing was reported at $149–$349 per month depending on dose, with insured patients potentially paying about $25/month using a Lilly discount card; Foundayo will be included in a Trump administration effort to lower GLP‑1 drug prices.
- Market context: more than 600,000 prescriptions have already been written for Novo Nordisk’s oral Wegovy since its December approval, and a KFF survey found about 1 in 8 U.S. adults have used injectable GLP‑1 drugs.
- Eli Lilly’s stock rose more than 4% in afternoon trading after the approval was announced.
- CBS Evening News confirmed the FDA approval in an explainer segment by Dr. Jon LaPook but added no new trial data, pricing figures, regulatory nuances, or quotes from FDA officials or Eli Lilly executives.
📊 Relevant Data
Epigenetic modifications, such as DNA methylation at specific sites, are associated with body mass index (BMI) in populations of African descent, potentially explaining a portion of the variation in obesity-related traits beyond genetic variants alone.
Epigenome-wide association study meta-analysis of BMI in African descent populations — PMC (National Library of Medicine)
Black and Hispanic patients with type 2 diabetes are less likely to be prescribed high-efficacy glucose-lowering medications like GLP-1 receptor agonists compared to White patients, with disparities observed in prescription rates across racial/ethnic groups.
Higher household income is independently associated with greater use of GLP-1 receptor agonists, while Black and Asian race and Hispanic ethnicity are linked to lower use, based on a national sample of adults with employer-sponsored insurance.
Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US — JAMA Health Forum
📰 Source Timeline (3)
Follow how coverage of this story developed over time
- This CBS item confirms in general terms that the FDA has approved a new Eli Lilly GLP‑1 weight‑loss drug but provides no additional specifics beyond what the earlier detailed story already carried.
- The segment is framed as an explainer by Dr. Jon LaPook rather than adding new trial data, pricing figures, or regulatory nuances.
- No new quotes from FDA officials or Eli Lilly executives are included in the text provided.
- Confirms the generic name orforglipron and reiterates the brand name Foundayo as a GLP‑1 pill mimicking natural appetite hormones.
- Specifies that FDA completed its review in 50 days under a new expedited-approval program aimed at cutting drug approval times.
- Provides concrete U.S. cash pricing ranges: $149–$349 per month depending on dose, with insured patients potentially paying $25/month via a Lilly discount card.
- States that more than 600,000 prescriptions have already been written for Novo Nordisk’s competing oral Wegovy pill since its December approval.
- Details that about 1 in 8 people in the U.S. have used injectable GLP‑1 drugs, citing a KFF survey.
- Clarifies that Foundayo will be included in a Trump administration deal to lower prices on GLP‑1 drugs.
- Reports that Eli Lilly’s stock rose more than 4% in Wednesday afternoon trading after the approval.
- Adds exact trial outcome wording from NEJM: 11.2% mean weight loss (~25 pounds) at 36 mg over more than 16 months vs 2.1% (~<5 pounds) on placebo, and that 5–10% of patients on orforglipron discontinued due to GI side effects vs nearly 3% on placebo.
- Reiterates usage distinction: orforglipron can be taken without fasting or timing restrictions, while the Wegovy pill must be taken on an empty stomach with a 30‑minute wait before eating or drinking.